HALIFAX,
Oct. 21, 2013 /CNW/ - MedMira Inc.,
(MedMira) (TSXV: MIR), a developer of rapid diagnostic technology
and solutions, has received an additional USD $1.917 million from the US Army. The Company
is currently developing and commercializing two rapid tests for
transfusion transmitted diseases under a United States Army Medical
Research Acquisition Activity (USAMRAA) contract.
The new funding enables MedMira to conduct
additional testing for the Reveal Rapid Hepatitis B Surface Antigen
Test and Multiplo Rapid HBc/HIV/HCV Antibody Test in parallel with
the current clinical trials. Testing of additional specimens will
provide the clinical data required for MedMira to obtain
complementary label claims and intended uses for these two
products, expanding their utility in a number of field
applications.
"The additional product testing that we can now
perform on the Reveal and Multiplo products will allow our
customers access to powerful diagnostic capabilities in a wider
range of environments and situations," said Kevin Jones, Senior Director, Global Sales &
Marketing, MedMira. "The end result of the additional funding
will be that more tests will be performed at a faster rate and a
lower cost than has previously been attainable. The benefits for
patients and healthcare providers using rapid tests built on our
technology platform, especially the Multiplo triple test, will be
seen not just in the US, but by organizations across the
globe."
MedMira foresees that the new testing will
demonstrate that the Reveal and Multiplo products are suitable for
additional uses beyond the original areas of interest on the
frontlines of military healthcare in emergency medical situations
and for screening transfusion transmitted diseases. Reveal and
Multiplo will also prove valuable in public healthcare initiatives
as well as disaster and humanitarian relief efforts globally.
About MedMira
MedMira is a leading developer and manufacturer
of flow-through rapid diagnostics. The Company's tests provide
hospitals, labs, clinics and individuals with reliable, rapid
diagnosis for infectious diseases in just three minutes. MedMira
tests are sold under the Reveal®, Multiplo™ and Miriad brands in
global markets. MedMira's rapid flow-through HIV test is the only
one in the world to achieve regulatory approvals in Canada, the United
States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova
Scotia, Canada. For more information visit
www.medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MEDMIRA INC.
